ECE2016 Eposter Presentations Thyroid cancer (81 abstracts)
Our experience with low doses of radioactive iodine (30 mCi) in patients with differentiated thyroid cancer
Inmaculada Prior-Sánchez 1 , Concepción Muñoz Jiménez 1 , Paloma Moreno Moreno 1 , Ángel Rebollo Román 1 , Ana Barrera Martín 1 , Estefanía Moreno Ortega 2 , Juan Antonio Vallejo Casas 2 & María Ángeles Gálvez Moreno 1
1Department of Endocrinology and Metabolism (Reina Sofia University Hospital, Córdoba), Cordoba, Andalucia, Spain; 2Department of Nuclear Medicine (Reina Sofia University Hospital, Córdoba), Cordoba, Andalucia, Spain.
Background: The management of patients with differentiated thyroid cancer (DTC) has been changing in recent years and aggressiveness of treatment depends on the risk of persistent or recurrent disease.
Objective: The aim of this study was to assess the efficacy of low doses of Radioactive Iodine (RAI;131I) therapy in patients with DTC.
Methods: We retrospectively evaluated all patients who were diagnosed with DTC (n=213) at a tertiary hospital center in Cordoba (Spain), between January 2000 and December 2013. In all patients included, initial treatment consisted of total or subsequent completion thyroidectomy, with or without lymphadenectomy, RAI ablation therapy at a dose of 30 mCi (n=17) or ≥100 mCi: 100 mCi (n=143), 150 mCi (n=5), 200 mCi (n=4). Demographic and clinical variables were compared between both groups of RAI therapy.
Results: Seventeen patients received a low dose of 131I (10♀; 7♂; 100% papillary). All subjects were classified as low risk of recurrence according to the revised ATA guidelines. Differences were found in the main prognostic factor as aggressive histological criteria (P=0.014), pTNM Stage (P=0.045), stimulated thyroglobulin (Stim-Tg) measured at 6–12 months (P=0.007). Statistically significant differences were not found in age (<45 or ≥45 years), sex, histology, total thyroidectomy or subsequent completion, neck lymphadenectomy, and the number of adverse effects. The hospitalization time was lower in the group of patients who received 30 mCi (6 hours us ≥48 hours; P<0.001). All of 17 patients had no evidence of disease after an average follow-up of 3.59 years. Up to now, recurrence has been detected in none of them.
Conclusions: Therapy with low doses of 131I (30 mCi) is an effective treatment in patients with low-risk of recurrence with de advantage of having a lower hospitalization time.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more